Pharmaceutical companies have historically been top-line focused. Due to a combination of patent law and block-buster drugs, they’ve been in a very strong position from a revenue standpoint (think Claratin, the little purple pill and the little blue pill). The model worked well for quite some time due to high volume, exclusivity and high prices [more]

[Read more →]

Jason Busch of SpendMatters recently hosted a number of podcasts with our Category and Commodity Managers (many of whom will be familiar names to regular Supply Excellence readers). The Category Chatter podcast series dives deep, sometimes very deep into the market trends, pitfalls and opportunities in each of these areas:

Low-Cost Country Sourcing - Jason and [more]

[Read more →]